Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency

FRANKFURT,Germany,Jan. 9,2025 -- Anbio Biotechnology ("Anbio"),a global leader in diagnostics innovation,announces the launch of its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000,a transformative technology designed to deliver rapid,reliable,and cost-effective diagnostic results. Tailored for diverse clinical settings,this solution addresses the growing demand for streamlined workflows and high-performance testing.

Anbio Dry Chemiluminescence Immunoassay System (ADL-1000)

Key Highlights of the Anbio Dry CLIA Solution

Revolutionary Freeze-Dried Reagents:

Eliminates the need for cold chain logistics,enabling room temperature storage and operation. Reagents remain stable without refrigeration,reducing costs and logistical challenges.

Advanced Whole Blood Testing:

Incorporates innovative onboard separation technology,directly processing whole blood into plasma for analysis. Results are derived without conversions,ensuring uncompromised accuracy.

Rapid Emergency Testing Capabilities:

Features a dedicated emergency testing slot for immediate processing. Delivers results for critical assays within 15 minutes,meeting the stringent turnaround time (TAT) requirements of emergency departments.

Compact and Efficient Design:

With a minimal footprint of 0.518m2,the system is optimized for space-constrained environments. It supports continuous operation with a throughput of 180 tests/hour.

Minimal Waste with Single-Test Flexibility:

Designed for single-use testing on demand,the system minimizes reagent waste,offering unparalleled operational efficiency.

Comprehensive Assay Portfolio:

Beyond traditional chemiluminescence applications,it supports advanced diagnostics for specialized conditions such as stroke,Alzheimer's disease,thrombosis,and pre-eclampsia. These unique assays expand the scope of diagnostic possibilities,catering to the evolving needs of modern medicine.

"The Anbio Dry CLIA Solution represents a significant advancement in diagnostic technology,offering unparalleled speed and accuracy while addressing the logistical challenges faced by healthcare providers worldwide,"said Michael Lau,CEO at Anbio Biotechnology.

About Anbio Biotechnology

Anbio Biotechnology is a leading global medical device company specializing in in vitro diagnostics. Its diverse portfolio spans multiple medical fields,including cancer,cardiovascular conditions,infectious diseases,hormones,inflammation,and drug testing. Through innovation and a dedication to accessibility,Anbio is redefining diagnostic care worldwide.

For more information about the Anbio Dry CLIA analyzer and Anbio's CE-marked Dry CLIA assays,follow Anbio on social media for the latest updates.